Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia
Guidelines for the measurement of BCR-ABL1 transcripts in chronic myeloid leukaemia
复制标题
DOI：
10.1111/j.1365-2141.2011.08603.x
复制
发表时间：
2011-04-01
影响因子：
6.5
通讯作者：
Cross, Nicholas C. P.
中科院分区：
文献类型：
--
作者：
Foroni, Letizia;Wilson, Gill;Cross, Nicholas C. P.
通过真实的时间定量聚合酶链反应（RT-qPCR）检测BCR-ABL1融合基因是监测慢性髓性白血病患者治疗反应的最敏感的常规方法。在酪氨酸激酶抑制剂（TKI）治疗的背景下，该技术最适用于已实现完全细胞遗传学缓解的患者，并可用于定义特定的治疗里程碑。为了有效地实现这一点，实验室程序的标准化和结果的解释是必不可少的。我们在此介绍了由英国和爱尔兰的21个检测实验室组成的联盟根据英国临床分子遗传学学会的程序起草并同意的RT-qPCR检测、数据解读和报告的共识最佳实践指南。
P>Molecular testing for the BCR-ABL1 fusion gene by real time quantitative polymerase chain reaction (RT-qPCR) is the most sensitive routine approach for monitoring the response to therapy of patients with chronic myeloid leukaemia. In the context of tyrosine kinase inhibitor (TKI) therapy, the technique is most appropriate for patients who have achieved complete cytogenetic remission and can be used to define specific therapeutic milestones. To achieve this effectively, standardization of the laboratory procedures and the interpretation of results are essential. We present here consensus best practice guidelines for RT-qPCR testing, data interpretation and reporting that have been drawn up and agreed by a consortium of 21 testing laboratories in the United Kingdom and Ireland in accordance with the procedures of the UK Clinical Molecular Genetics Society.